Valneva & Pfizer Report Positive Pediatric, Adolescent Phase 2 Booster Results for VLA15

Valneva SE and Pfizer Inc. announced, in a press release, data Lyme disease vaccine candidateshowing positive pediatric and adolescent immunogenicity and safety for, VLA15, their Lyme disease vaccine candidate, when administered as a booster. These results, taken from the Phase 2 study one month after the booster dose, showed a notable anamnestic antibody response in pediatric and adolescent participants as well as in adults.

For more information:

Read the press release on

Read LDA President’s Blog discussing the August 2023 Bloomberg vaccine article.

Read more about the VLA15 Lyme disease vaccine.